During the comparator trial , compared with women randomized to alendronate 10 mg , women randomized to teriparatide 40 microg had reduced risk for any back pain ( relative risk 0.27 , 95 % CI 0.09-0 .82 ) and moderate or severe back pain ( relative risk 0.19 , 95 % CI 0.04-0 .86 ) .
